Equipped with a unique understanding of the immune suppressive dynamics that allow cancer cells to grow and spread in the body, we are moving beyond T-cell targeted therapies to develop novel biotherapeutics that navigate and disarm immune suppression and tumor infiltration.
Immune-Onc’s lead program, an antibody targeting an immune inhibitory receptor, is being explored as a potential candidate in the treatment of acute ...
Equipped with a unique understanding of the immune suppressive dynamics that allow cancer cells to grow and spread in the body, we are moving beyond T-cell targeted therapies to develop novel biotherapeutics that navigate and disarm immune suppression and tumor infiltration.
Immune-Onc’s lead program, an antibody targeting an immune inhibitory receptor, is being explored as a potential candidate in the treatment of acute myeloid leukemia (AML) and other cancers.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.